A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Conditions:   Receptors, Estrogen;   Genes, Erbb-2;   Breast Neoplasms Interventions:   Drug: Palbociclib (75, 100, 125 milligram [mg]);   Drug: H3B-6545 (300, 450 mg) Sponsors:   H3 Biomedicine Inc.;   Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials